Source | Utility decrement for minor bleeds |
 EQ-5D-5 L UK tariff - PA | −0.000848 |
 EQ-5D-5 L to EQ-5D-3 L US value set - PA | −0.00137 |
 EQ-5D-5 L to EQ-5D-3 L UK value set - PA | −0.00140 |
 EQ-5D-3 L US tariff - PA | −0.00180 |
 Garg [28] | − 0.002 |
 EQ-5D-3 L UK tariff - PA | −0.00250 |
 Kazi [29] | −0.004 |
 EQ-5D-5 L UK tariff - SA | −0.00453 |
 EQ-5D-5 L to EQ-5D-3 L US value set - SA | −0.00566 |
 EQ-5D-3 L US tariff - SA | −0.00584 |
 EQ-5D-5 L to EQ-5D-3 L UK value set - SA | −0.00661 |
 EQ-5D-3 L UK tariff - SA | −0.00828 |
 Liew [30] | − 0.02 |
 Amin [11] | −0.0257 (BARC type 1) |
Source | Utility decrement for major bleeds |
 Schleinitz [32] | −0.005 (GI bleeding) |
 Greenhalgh [27] | − 0.007 |
 Kazi [29] | −0.01 (CABG-related) |
 Gupta [31] | −0.016 (GI haemorrhage) |
 EQ-5D-5 L to EQ-5D-3 L US value set - PA | −0.0187 |
 Wang [35] | − 0.02 (bleeding in general) |
 EQ-5D-3 L US tariff - PA | −0.0203 |
 EQ-5D-5 L UK tariff - PA | −0.0222 |
 Garg [28] | − 0.025 |
 EQ-5D-5 L to EQ-5D-3 L UK value set - PA | −0.0258 |
 EQ-5D-3 L UK tariff - PA | −0.0297 |
 Kazi [29] | − 0.0308 (extra-cranial) |
 Amin [11] | −0.0381 (BARC type 2–4) |
 EQ-5D-5 L to EQ-5D-3 L US value set - SA | −0.0405 |
 EQ-5D-3 L US tariff - SA | −0.0441 |
 Amin [11] | − 0.0445 (BARC type 3–4) |
 EQ-5D-5 L UK tariff - SA | − 0.0465 |
 Liew [30] | −0.05 |
 EQ-5D-5 L to EQ-5D-3 L UK value set - SA | −0.0552 |
 EQ-5D-3 L UK tariff - SA | −0.0621 |
 Latour-Perez [33] | − 0.13 (serious haemorrhage) |
 Jiang [34] | −0.250 (non-fatal bleeding) |
 Jiang [36] | −0.250 (non-fatal bleeding) |